Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

Bowlus C, Pockros P, Kremer A, Pares A, Forman L, Drenth JP, Ryder S, Malecha ES, Pencek R, Iloeje U, Macconell L, Shapiro D, Pierre B (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Journal of Hepatology Elsevier

Publisher: ELSEVIER SCIENCE BV

City/Town: AMSTERDAM

Pages Range: S111-S112

Conference Proceedings Title: JOURNAL OF HEPATOLOGY

Event location: Paris FR

DOI: 10.1016/s0168-8278(18)30441-0

Authors with CRIS profile

Andreas Kremer Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Intercept Pharmaceuticals US United States (USA) (US) Scripps Research Institute (TSRI) US United States (USA) (US) Nottingham University Hospitals GB United Kingdom (GB) Radboud University Nijmegen NL Netherlands (NL) University of California Davis (UCDAVIS) US United States (USA) (US) Universitat de Barcelona (UB) / University of Barcelona ES Spain (ES) University of Colorado System US United States (USA) (US)

How to cite

APA:

Bowlus, C., Pockros, P., Kremer, A., Pares, A., Forman, L., Drenth, J.P.,... Pierre, B. (2018). Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC). In JOURNAL OF HEPATOLOGY (pp. S111-S112). Paris, FR: AMSTERDAM: ELSEVIER SCIENCE BV.

MLA:

Bowlus, C., et al. "Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)." Proceedings of the International Liver Congress (ILC), Paris AMSTERDAM: ELSEVIER SCIENCE BV, 2018. S111-S112.

BibTeX: Download